Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Natural Human Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu in Perth, Western Australia.

Next Previous
Trial Profile

Evaluation of Natural Human Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu in Perth, Western Australia.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon alpha (Primary)
  • Indications Common cold; Influenza virus infections
  • Focus Therapeutic Use
  • Sponsors Ainos; Amarillo Biosciences

    • Most Recent Events

    • 09 Apr 2010 The final report of the results from this trial has been submitted to the State Health Research Advisory Council of the DOH, Western Austrlia, and have been published on the Amarillo Biosciences website according to an Amarillo Biosciences media release.
    • 16 Feb 2010 According to an Amarillo Biosciences media release, a substudy in older participants indicated a benefit in preventing influenza-like illness.
    • 05 Feb 2010 Status changed from active, no longer recruiting to completed, according to an Amarillo Biosciences media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top